DK3077389T3 - Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister - Google Patents

Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister

Info

Publication number
DK3077389T3
DK3077389T3 DK14824107.8T DK14824107T DK3077389T3 DK 3077389 T3 DK3077389 T3 DK 3077389T3 DK 14824107 T DK14824107 T DK 14824107T DK 3077389 T3 DK3077389 T3 DK 3077389T3
Authority
DK
Denmark
Prior art keywords
methanon
methylpyrrolidin
chlor
triazol
imidazol
Prior art date
Application number
DK14824107.8T
Other languages
English (en)
Inventor
Christoph Boss
Christine Brotschi
Markus Gude
Bibia Heidmann
Thierry Sifferlen
Raumer Markus Von
Jodi T Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3077389T3 publication Critical patent/DK3077389T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK14824107.8T 2013-12-03 2014-12-02 Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister DK3077389T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013060596 2013-12-03
PCT/IB2014/066508 WO2015083070A1 (en) 2013-12-03 2014-12-02 Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
DK3077389T3 true DK3077389T3 (da) 2017-11-13

Family

ID=52282786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14824107.8T DK3077389T3 (da) 2013-12-03 2014-12-02 Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister

Country Status (31)

Country Link
US (1) US9914720B2 (da)
EP (1) EP3077389B1 (da)
JP (1) JP6496733B2 (da)
KR (1) KR102361418B1 (da)
CN (1) CN105793257B (da)
AU (1) AU2014358742B2 (da)
CA (1) CA2929423C (da)
CL (1) CL2016001342A1 (da)
CY (1) CY1119695T1 (da)
DK (1) DK3077389T3 (da)
EA (1) EA030137B1 (da)
ES (1) ES2651475T3 (da)
HK (1) HK1225731B (da)
HR (1) HRP20171773T1 (da)
HU (1) HUE035731T2 (da)
IL (1) IL245923B (da)
LT (1) LT3077389T (da)
MA (1) MA39163B1 (da)
MX (1) MX364208B (da)
MY (1) MY179862A (da)
NO (1) NO3077389T3 (da)
NZ (1) NZ721438A (da)
PH (1) PH12016500988A1 (da)
PL (1) PL3077389T3 (da)
PT (1) PT3077389T (da)
SA (1) SA516371231B1 (da)
SI (1) SI3077389T1 (da)
TW (1) TWI664177B (da)
UA (1) UA119549C2 (da)
WO (1) WO2015083070A1 (da)
ZA (1) ZA201604499B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2855453T3 (da) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-prolinderivater
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MX366642B (es) 2013-12-04 2019-07-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina.
CN110612291B (zh) * 2017-05-03 2024-02-13 爱杜西亚药品有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
US20230134935A1 (en) 2020-04-19 2023-05-04 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
EP4289834A1 (en) * 2021-02-02 2023-12-13 Medshine Discovery Inc. Tetrahydropyrrolocyclic compound and application thereof
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
EP1289955B1 (en) 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
MXPA03003039A (es) 2000-10-06 2003-10-15 Neurogen Corp Derivados de indola y bencimidazola como moduladores del receptor crf.
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
EP1435955A2 (en) 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
ES2299567T3 (es) 2001-05-05 2008-06-01 Smithkline Beecham Plc N-aroilaminas ciclicas.
HUP0400326A2 (hu) * 2001-06-28 2004-09-28 Smithkline Beecham P.L.C. Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US20060040937A1 (en) 2002-09-18 2006-02-23 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
EP1751111B1 (en) 2004-03-01 2014-12-31 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
MX2008011647A (es) 2006-03-15 2008-09-22 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolina para mejorar la funcion de la memoria.
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
PL2069332T3 (pl) 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Związki azetydynowe jako antagoniści receptorów oreksynowych
US20100016401A1 (en) 2006-09-29 2010-01-21 Actelion Phamaceuticals Ltd. 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CN101711247A (zh) 2007-05-14 2010-05-19 埃科特莱茵药品有限公司 2-环丙基-噻唑衍生物
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
ATE524466T1 (de) 2007-07-03 2011-09-15 Actelion Pharmaceuticals Ltd 3-azabicycloä3.3.0üoktanverbindungen
US20090022670A1 (en) 2007-07-03 2009-01-22 Giuseppe Alvaro Novel compounds
CA2693820A1 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
EP2185512B1 (en) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Trans-3-aza-bicyclo[3.1.0]hexane derivatives
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CA2713184A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US20110105491A1 (en) 2008-07-07 2011-05-05 Hamed Aissaoui Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
EP2370426A1 (en) 2008-12-02 2011-10-05 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof
JP2012510493A (ja) 2008-12-02 2012-05-10 グラクソ グループ リミテッド N−{[(ir、4s、6r)−3−(2−ピリジニルカルボニル)−3−アザビシクロ[4.1.0]ヘプタ−4−イル]メチル}−2−ヘテロアリールアミン誘導体およびその使用
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
AU2010240871A1 (en) 2009-04-24 2011-10-27 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
JP5987005B2 (ja) 2011-02-18 2016-09-06 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン拮抗薬として有用な新規なピラゾール及びイミダゾール誘導体
SG11201401665WA (en) 2011-11-08 2014-09-26 Actelion Pharmaceuticals Ltd 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
DK2855453T3 (da) * 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-prolinderivater
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
JP2016510810A (ja) 2013-03-12 2016-04-11 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MX366642B (es) 2013-12-04 2019-07-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina.

Also Published As

Publication number Publication date
CA2929423C (en) 2021-12-07
EP3077389B1 (en) 2017-09-13
AU2014358742A1 (en) 2016-07-07
TWI664177B (zh) 2019-07-01
JP2016539136A (ja) 2016-12-15
CA2929423A1 (en) 2015-06-11
KR20160092015A (ko) 2016-08-03
MX364208B (es) 2019-04-16
ES2651475T3 (es) 2018-01-26
AU2014358742B2 (en) 2019-02-07
US20160368901A1 (en) 2016-12-22
HK1225731B (zh) 2017-09-15
HRP20171773T1 (hr) 2017-12-29
ZA201604499B (en) 2019-04-24
CY1119695T1 (el) 2018-04-04
WO2015083070A1 (en) 2015-06-11
EP3077389A1 (en) 2016-10-12
PT3077389T (pt) 2017-12-15
PH12016500988B1 (en) 2016-06-20
BR112016012628A2 (da) 2017-08-22
US9914720B2 (en) 2018-03-13
HUE035731T2 (hu) 2018-05-28
PH12016500988A1 (en) 2016-06-20
PL3077389T3 (pl) 2018-03-30
CN105793257B (zh) 2018-11-13
EA201600435A1 (ru) 2016-11-30
IL245923B (en) 2019-09-26
EA030137B1 (ru) 2018-06-29
JP6496733B2 (ja) 2019-04-03
KR102361418B1 (ko) 2022-02-09
NO3077389T3 (da) 2018-02-10
CN105793257A (zh) 2016-07-20
MA39163B1 (fr) 2018-09-28
SI3077389T1 (en) 2018-01-31
MX2016007215A (es) 2016-09-07
LT3077389T (lt) 2017-12-11
UA119549C2 (uk) 2019-07-10
CL2016001342A1 (es) 2016-11-18
NZ721438A (en) 2021-12-24
SA516371231B1 (ar) 2018-02-20
IL245923A0 (en) 2016-08-02
TW201605838A (zh) 2016-02-16
BR112016012628A8 (pt) 2017-12-26
MA39163A1 (fr) 2017-11-30
MY179862A (en) 2020-11-18

Similar Documents

Publication Publication Date Title
DK3077389T3 (da) Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister
DK3077390T3 (da) Krystallinsk saltform af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon som orexinreceptorantagonist
DK3395814T3 (da) Hæmmere af fibroblastvækstfaktorreceptoren
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK2970423T3 (da) Interleukin-2 muteiner for udvidelsen af t-regulatoriske celler
DK3212901T3 (da) Anvendelse af (2e)-1,1,1,4,5,5,5-heptafluor-4-(trifluormethyl)pent-2-en i effektcyklusser
DK2994488T3 (da) Anvendelse af c5ar-antagonister
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK3254092T3 (da) Bestemmelse af en vægs termiske modstand
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
MA40858A (fr) Composés antagonistes des récepteurs d3 à la dopamine
DK3104847T3 (da) Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
DK2991976T3 (da) Syntese af 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidin-2,6-dion
DK3334721T3 (da) Cgrp-receptorantagonister
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
DK3303323T3 (da) Heterocykliske forbindelser af 3,3-difluorpiperidincarbamat som NR2B-NMDA-receptorantagonister
DK3328395T3 (da) Ny brug af dextransulfat
ZA201704462B (en) New benzimidazole derivatives as antihistamine agents
DK3132684T3 (da) Behandling af fiskepopulationer med lufenuron
DK3310756T3 (da) Thromboxanreceptorantagonister
CL2015003180A1 (es) Composicion interpolimera de etileno / alfa - olefina
DK3172867T3 (da) Netværksarkitektur med fast routing
DK3143019T3 (da) Krystallinsk form af 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinolin-1-carbonitril
DK2943185T3 (da) Formuleringer med langvarig frigivelse af lorazepam